微RNAs在骨质疏松症发生发展中的作用及临床应用前景  

Role and clinical application prospects of microRNAs in development of osteoporosis

作　　者：舒建川 杨程显 李戈 于峥嵘[1] 李淳德[1] SHU Jianchuan;YANG Chengxian;LI Ge;YU Zhengrong;LI Chunde(Department of Orthopaedics,Peking University First Hospital,Beijing 100034;Department of Endocrinology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院骨科,北京100034 [2]北京大学第一医院内分泌科,北京100034

出　　处：《中华骨与关节外科杂志》2023年第5期471-480,共10页Chinese Journal of Bone and Joint Surgery

基　　金：国家自然科学基金(82101554);中央高水平医院临床科研业务费资助(2023IR18)。

摘　　要：骨质疏松症(OP)是一种常见的代谢性骨病,受遗传和环境因素影响,增加骨脆性和骨折的风险,从而严重影响患者的生活质量。越来越多的证据表明,遗传和环境因素通过表观遗传机制影响OP的发生发展。微RNAs(miRNAs)作为表观调控因子,能够调控成骨细胞和破骨细胞相关信号分子的表达,在骨代谢过程中发挥重要的调节作用。本文总结miRNAs调节成骨细胞和破骨细胞分化对OP的影响机制及miRNAs在临床应用中的探索,以期为开发OP诊疗的新方法提供一定的参考。Osteoporosis is a common metabolic bone disease that is influenced by genetic and environmental factors,increasing the risk of bone fragility and fractures,thus seriously affecting the quality of life of patients.Growing evidence suggests that genetic and environmental factors contribute to the development of osteoporosis through epigenetic mechanisms.As epigenetic regulators,microRNAs(miRNAs)can regulate the expression of osteoblast-and osteoclast-related signaling molecules,and play an important regulatory role in the process of bone metabolism.In this paper,by summarizing the mechanism of miRNAs regulating osteoblast and osteoclast differentiation on osteoporosis and the emerging role of miRNAs in clinical practice,we hope to provide help for the exploration of new methods for the diagnosis and treatment of osteoporosis.

关 键 词：骨质疏松症 微RNAS 成骨细胞 破骨细胞 

分 类 号：R589[医药卫生—内分泌]